{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:34:22Z","timestamp":1791646462120,"version":"4.3.4"},"reference-count":101,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Patients with cirrhosis were long thought to be coagulopathic. However, this paradigm has changed in recent years and currently, cirrhosis is recognised as a prothrombotic state. Due to the increasing incidence of cirrhosis from nonalcoholic steatohepatitis which is closely associated with cardiac disease, patients with cirrhosis increasingly require therapy with anticoagulants and antiplatelet agents. However, their potential for causing catastrophic and life\u2010threatening bleeding in patients with cirrhosis leads to hesitancy about their use in patients with cirrhosis. Overall, traditional anticoagulation is safe for all Child\u2010Pugh classes while newer direct oral anticoagulants (DOACs) are mostly safe in Child\u2010Pugh class A\/B and contraindicated in severe hepatic impairment. For different indications, published data to date suggest that anticoagulation is overall safe for patients with cirrhosis who have venous thromboembolism, atrial fibrillation and portal vein thrombosis, and does not increase the risk of variceal bleeding. Moreover, DOACs appear to have similar safety profiles as traditional anticoagulants. Finally, most studies suggest that antiplatelet agents are also safe to use in patients with cirrhosis although they are mostly contraindicated in severe hepatic impairment. For both anticoagulants and antiplatelet agents, severe thrombocytopaenia presents a relative contraindication to their use. More prospective trials and large cohort studies are needed to advance our understanding of the safety and nuances of DOACs and antiplatelet agents in patients with advanced cirrhosis.<\/jats:p>","DOI":"10.1111\/apt.17297","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T09:54:29Z","timestamp":1668419669000},"page":"52-71","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Review article: the safety of anticoagulants and antiplatelet agents in patients with cirrhosis"],"prefix":"10.1111","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2920-7673","authenticated-orcid":false,"given":"Jiayi","family":"Ma","sequence":"first","affiliation":[{"name":"Indiana University School of Medicine and Indiana University Health  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4082-3178","authenticated-orcid":false,"given":"Naga P.","family":"Chalasani","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine and Indiana University Health  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"Schwantes\u2010An","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Medical &amp; Molecular Genetics  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8392-0632","authenticated-orcid":false,"given":"Einar Stef\u00e1n","family":"Bj\u00f6rnsson","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Landspitali University Hospital  Reykjavik Iceland"},{"name":"Faculty of Medicine University of Iceland  Reykjavik Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.34"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i13.2115"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14018"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21327"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620\u2010009\u20100738\u2010z"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.500020604"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000486"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100038\u20101666861"},{"key":"e_1_2_8_10_1","unstructured":"FDA.Coumadin.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/009218s107lbl.pdf"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1293"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cld.946"},{"key":"e_1_2_8_13_1","unstructured":"FDA.Heparin sodium.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/017037Orig1s187lbl.pdf"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088390"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.006"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/meg.0000000000000351"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41424\u2010018\u20100043\u20102"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41395\u2010018\u20100421\u20100"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620\u2010020\u201006695\u20104"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31646"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.11.026"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.07.040"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024489"},{"key":"e_1_2_8_24_1","unstructured":"FDA.Fondaparinux.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021345Orig1s043lbl.pdf"},{"key":"e_1_2_8_25_1","unstructured":"EMA.Arixtra.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/arixtra\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_8_26_1","unstructured":"FDA.Dabigatran.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/022512s041lbl.pdf"},{"key":"e_1_2_8_27_1","unstructured":"EMA.Pradaxahttps:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/pradaxa\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008324179"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.118.036710"},{"key":"e_1_2_8_30_1","unstructured":"FDA.Apixaban.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202155s034lbl.pdf"},{"key":"e_1_2_8_31_1","unstructured":"EMA.Eliquis.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/eliquis\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268\u2010021\u201000359\u2010y"},{"key":"e_1_2_8_33_1","unstructured":"FDA.Edoxabanhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/206316s017lbl.pdf"},{"key":"e_1_2_8_34_1","unstructured":"EMA.Lixiana.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/lixiana\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.550"},{"key":"e_1_2_8_36_1","unstructured":"FDA.Rivaroxabanhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022406Orig1s039 202439Orig1s038correctedlbl.pdf"},{"key":"e_1_2_8_37_1","unstructured":"EMA.Xarelto.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/xarelto\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12054"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510991"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000885"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.04.042"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cld.336"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.12.001"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003\u20104819\u2010146\u201012\u2010200706190\u201000007"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000208294.46968.a4"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302507"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306638"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620\u2010015\u20104012\u20102"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12844"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239\u2010019\u201002035\u20100"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14992"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.12788\/fp.0058"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620\u2010008\u20100265\u20103"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1160\/th16\u201006\u20100450"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.27"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3827.3827"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13459"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31264"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1097\/fjc.0000000000000513"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.11.183"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13045"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.01.097"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.118.011112"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.04.052"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.042796"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14121"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/meg.0000000000001846"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2018.05.002"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12895"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00508\u2010018\u20101351\u2010y"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000228"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.10.016"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.018"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1097\/mcg.0000000000000733"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2019.01.006"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478\u20103231.2012.02785.x"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2015150369"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2013.08.018"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2014.20.4.384"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e328357d5d4"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27783"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v13.i11.599"},{"key":"e_1_2_8_85_1","unstructured":"PDR.Aspirin.https:\/\/www.pdr.net\/drug\u2010summary\/Bayer\u2010Low\u2010Dose\u2010Aspirin\u2010Regimen\u2010aspirin\u20103799"},{"key":"e_1_2_8_86_1","unstructured":"Bayer.Aspirinhttps:\/\/www.livewell.bayer.com\/deco\/omr\/aspirin\u2010regimen\u2010bayer\u2010low\u2010dose\u201081\u2010mg.pdf"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/bf00543800"},{"key":"e_1_2_8_88_1","unstructured":"FDA.Clopidogrel.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020839s074lbl.pdf"},{"key":"e_1_2_8_89_1","unstructured":"EMA.Plavix.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/plavix\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912700022008973"},{"key":"e_1_2_8_91_1","unstructured":"FDA.Prasugrel.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022307s018lbl.pdf"},{"key":"e_1_2_8_92_1","unstructured":"EMA.Efient.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/efient\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102710.2009.01067.x"},{"key":"e_1_2_8_94_1","unstructured":"FDA.Ticagrelorhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022433s034lbl.pdf"},{"key":"e_1_2_8_95_1","unstructured":"EMA.Brilique.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/brilique\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010379409"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223380"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.25067"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14121"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3182371258"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102036.2012.05225.x"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.44.2.270"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.17297","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/apt.17297","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.17297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T22:26:27Z","timestamp":1692311187000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.17297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/apt.17297"],"URL":"https:\/\/doi.org\/10.1111\/apt.17297","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]},"assertion":[{"value":"2022-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}